BSE filing, NSE: BROOKS. Summary written from the filing by ALFA Finder's alert engine.
Brooks Laboratories Ltd: key numbers
- Share price
- ₹59.90
- Market cap
- ₹176.4 Cr
- Revenue (annual)
- ₹85.74 Cr
- Net profit (annual)
- ₹24.58 Cr
- P/E (TTM)
- 13.4×Sector 46.1×
- Promoter holding
- 52.62%+0.00% QoQ
- FII holding
- 0.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Brooks Laboratories Ltd
All →Brooks Laboratories Other Announcement
Brooks Laboratories Ltd has submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI regulatory requirements.
Brooks Laboratories Price Movement Clarification
Brooks Laboratories informed BSE it has no additional material information to disclose regarding the recent price movement. The company attributed the share price and volume changes to purely market-driven factors.
Brooks Laboratories Management Change
Brooks Laboratories Ltd announced the resignation of Ms. Krutika Rane, Company Secretary and Compliance Officer, effective October 9, 2026.
Brooks Laboratories Annual General Meeting
Brooks Laboratories Limited conducted its 24th Annual General Meeting on September 3, 2026. Shareholders transacted ordinary business, including the adoption of financial statements and director appointments.
Brooks Laboratories Annual General Meeting
Brooks Laboratories issued an addendum to its 24th Annual General Meeting notice. The amendment modifies Resolution No. 4 regarding corporate guarantee arrangements.
Brooks Laboratories Q1 FY27 Results: Net Loss of ₹1.8 Cr
Brooks Laboratories Ltd reported revenue from operations of ₹23 Cr (-9.8% YoY) and a net loss of ₹1.8 Cr for Q1 FY27.
- Key figure
- Net loss ₹1.8 Cr
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr